Literature DB >> 25969544

EGFR-activated Src family kinases maintain GAB1-SHP2 complexes distal from EGFR.

Christopher M Furcht1, Janine M Buonato1, Matthew J Lazzara2.   

Abstract

Complexes of signaling proteins that are nucleated upon activation of receptor tyrosine kinases are dynamic macromolecular assemblies held together by interactions, such as the recognition of phosphotyrosines by Src homology 2 (SH2) domains. We predicted that reversible binding and phosphatase activity enable dynamic regulation of these protein complexes, which could affect signal transduction. We explored how dynamics in the interactions among the epidermal growth factor (EGF) receptor (EGFR), GRB2-associated binder protein 1 (GAB1), and SH2 domain-containing phosphatase 2 (SHP2) affected EGFR signaling output, specifically SHP2 binding to tyrosine-phosphorylated GAB1, which relieves the autoinhibition of SHP2. Among the effects of activated SHP2 is increased extracellular signal-regulated kinase (ERK) activity. We found that in H1666 lung adenocarcinoma cells, EGFR-activated Src family kinases (SFKs) counteracted repeated GAB1 dephosphorylation events and maintained the association of SHP2 with phosphorylated GAB1 at a cytosolic site distal from EGFR. A computational model predicted that an experimentally verified delay in SFK inactivation after EGFR inactivation, combined with an amplification of GAB1 phosphorylation in cells with proteins in a specific range of concentrations, enabled GAB1 phosphorylation and GAB1-SHP2 complexes to persist longer than EGFR phosphorylation persisted in response to EGF. This SFK-dependent mechanism was specific to EGFR and did not occur in response to activation of the receptor tyrosine kinase c-MET. Thus, our results quantitatively describe a regulatory mechanism used by some receptor tyrosine kinases to remotely control the duration of a signal by regulating the persistence of a signaling protein complex.
Copyright © 2015, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25969544     DOI: 10.1126/scisignal.2005697

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  12 in total

Review 1.  Cell signaling regulation by protein phosphorylation: a multivariate, heterogeneous, and context-dependent process.

Authors:  Evan K Day; Nisha G Sosale; Matthew J Lazzara
Journal:  Curr Opin Biotechnol       Date:  2016-07-06       Impact factor: 9.740

2.  MECHANISTIC AND DATA-DRIVEN MODELS OF CELL SIGNALING: TOOLS FOR FUNDAMENTAL DISCOVERY AND RATIONAL DESIGN OF THERAPY.

Authors:  Paul J Myers; Sung Hyun Lee; Matthew J Lazzara
Journal:  Curr Opin Syst Biol       Date:  2021-06-09

3.  Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance.

Authors:  Kristina B Emdal; Antje Dittmann; Raven J Reddy; Rebecca S Lescarbeau; Sheri L Moores; Sylvie Laquerre; Forest M White
Journal:  Mol Cancer Ther       Date:  2017-08-22       Impact factor: 6.261

4.  Data-Driven Computational Modeling Identifies Determinants of Glioblastoma Response to SHP2 Inhibition.

Authors:  Evan K Day; Qing Zhong; Benjamin Purow; Matthew J Lazzara
Journal:  Cancer Res       Date:  2021-02-11       Impact factor: 13.312

Review 5.  An Updated View on the Rck Invasin of Salmonella: Still Much to Discover.

Authors:  Julien Mambu; Isabelle Virlogeux-Payant; Sébastien Holbert; Olivier Grépinet; Philippe Velge; Agnès Wiedemann
Journal:  Front Cell Infect Microbiol       Date:  2017-12-08       Impact factor: 5.293

6.  Assay to visualize specific protein oxidation reveals spatio-temporal regulation of SHP2.

Authors:  Ryouhei Tsutsumi; Jana Harizanova; Rabea Stockert; Katrin Schröder; Philippe I H Bastiaens; Benjamin G Neel
Journal:  Nat Commun       Date:  2017-09-06       Impact factor: 14.919

Review 7.  Insulin receptor endocytosis in the pathophysiology of insulin resistance.

Authors:  Catherine Hall; Hongtao Yu; Eunhee Choi
Journal:  Exp Mol Med       Date:  2020-06-23       Impact factor: 8.718

8.  TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.

Authors:  D-W Wu; T-C Chen; H-S Huang; H Lee
Journal:  Cell Death Dis       Date:  2016-06-30       Impact factor: 8.469

9.  Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression.

Authors:  Yao-Chen Wang; De-Wei Wu; Tzu-Chin Wu; Lee Wang; Chih-Yi Chen; Huei Lee
Journal:  Int J Biol Sci       Date:  2018-01-11       Impact factor: 6.580

10.  Reverting doxorubicin resistance in colon cancer by targeting a key signaling protein, steroid receptor coactivator.

Authors:  Sang Xiong; Gong-Wei Xiao
Journal:  Exp Ther Med       Date:  2018-02-28       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.